Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024

Semaglutide improves exercise function in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) in a secondary analysis of the prespecified pooled STEP-HFpEF and STEP-HFpEF DM trials presented at HFSA 2024.

An analysis of the EXPANDed patient-level pooled cohort presented at HFSA 2024 demonstrates clinical benefits in patients with atrial SMR at 1 year following a mitral TEER procedure using newer-generation clip devices. These included a significant reduction in MR and substantial improvements in PROs

The HeartMate 3 left ventricular assist device (LVAD) can offer a lifeline to patients with severe heart failure, including those with morbid obesity and advanced chronic kidney disease (CKD), medical conditions that carry increased perioperative risks, as suggested in a retrospective cohort study.

Treatment with the investigational agent acoramidis significantly reduced all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at 30 months for patients with transthyretin amyloid cardiomyopathy (ATTR-CM), according to a post hoc analysis of the phase III ATTRibute-CM trial presented at HFSA 2024.

In the treatment of patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), the use of the small interfering ribonucleic acid (siRNA) vutrisiran helps reduce and maintain the stability of NT-proBNP and troponin I—biomarkers associated with increased mortality in this population, as reported in a late-breaking clinical research presentation in HFSA 2024.

Treatment with mavacamten results in improvements in cardiac biomarkers of wall stress and injury, as shown by reduced NT-proBNP and troponin, without sustained left ventricular ejection fraction (LVEF) reductions, according to the preliminary findings of the EMBARK-HFpEF trial.

Treatment with HU6, a novel, first-in-class controlled metabolic accelerator, significantly reduces body weight while preserving lean body mass in patients with obesity-related heart failure with preserved ejection fraction (HFpEF), according to the HuMAIN-HFpEF* trial presented at HFSA 2024.